Stemgent to Supply Stem Cell Related Reagents from Pfizer
Deal covers small molecules to be sold as off-the-shelf products for nonclinical experiments.
ChromoCure signed a letter of intent to acquire Genome Research Group (GRG). The merger transaction is valued to be in excess of $25 million. ChromoCure claims the combination of GRC’s platforms with its own chromosomal-scanning technology will strengthen its capabilities in cancer detection and therapy by providing on-demand, real-time cancer progression analysis to monitor treatment efficacy.
GRG develops and provides cancer-detection systems and related therapeutic technologies. It claims that its Therapeutic Modeling Protocols are effective in detecting cancers at all stages. The firm has also developed therapeutic-modeling protocols and algorithms utilizing hypothermic modulation and resonance for the nontoxic and noninvasive treatment of cancer.
ChromoCure develops technologies based on the chromosomal theory of cancer. The company has tools, designs, protocols, and algorithms for cancer detection. It says that it has also developed a platform that scans suspect cells for the presence or absence of the chromosomal condition common to all cancers at all stages. In addition to cancer detection the firm is also using its understanding of cancer’s chromosomal properties for the potential development of effective, nontoxic therapeutic strategies.